Charles has deep experience in healthcare innovation. Over the past thirty years, he has served in various roles including General Partner at SV Life Sciences, Managing Director with Versant Ventures and numerous board director roles to help advance healthcare innovation. Charles is also a non-exec Chair of Ocular Therapeutix (OCUL).

Andy is a serial entrepreneur with a mission to advance health and human life. Currently he is Founder and CEO at Koya Medical, a growth stage venous and lymphatic solution and board director at Rivermark Medical. Previously, he headed Santen’s US surgical intraocular lens business (licensed as enVista IOL to Bausch &; Lomb) and headed operations at Oculeve
(acquired by Allergan).

Dan is an experienced clinical and regulatory executive. Initially with Cooper Surgical and subsequently with Alcon, Dan then led clinical and regulatory affairs with AVS (acquired by Santen) and Oculeve (acquired by Allergan).

Mark brings years of experience as an accomplished surgeon and Key Opinion Leader across all aspects of ophthalmology. He has advised numerous companies on clinical and medical affairs, helping companies navigate from concept through regulatory approval.